Infinity Pharmaceuticals Inc. Reports Updated Phase 1 Data Of IPI-145 In Indolent Non-Hodgkin Lymphoma At American Society of Hematology Annual Meeting

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced updated Phase 1 data from an ongoing study of IPI-145, its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), a potentially fatal hematologic malignancy (blood cancer). Data from the study showed that IPI-145 was clinically active, with an overall response rate of 73 percent, including three complete responses, among patients receiving IPI-145 dosed at = 25 mg twice daily (BID).

Help employers find you! Check out all the jobs and post your resume.

Back to news